GEN-1184 is a monoclonal antibody conjugated commercialized by Genmab, with a leading Phase II program in Epithelial Ovarian Cancer. According to Globaldata, it is involved in 4 clinical trials, of which 1 is ongoing, and 3 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of GEN-1184’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for GEN-1184 is expected to reach an annual total of $52 mn by 2039 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
GEN-1184 Overview
GEN-1184 is under development for the treatment of solid tumors such as non small cell lung cancer, ovarian cancer, endometrial cancer, breast cancer (HER2 negative breast cancer, primary peritoneal cancer, fallopian tube cancer, malignant mesothelioma, triple-negative breast cancer and unspecified indication. It is an antibody drug conjugate (ADC) bearing a topoisomerase 1 inhibitor payload which acts by targeting FOLR1 alpha receptor. It acts by targeting folate receptor alpha. It is administered through intravenous route.
Genmab Overview
Genmab is a biotechnology company that develops differentiated human antibody therapies for the treatment of cancer and other diseases. The company’s marketed antibodies include ofatumumab (Kesimpta) for the treatment of relapsing multiple sclerosis, daratumumab (Darzalex) for the treatment of AL amyloidosis and multiple myeloma, and teprotumumab (Tepezza) for thyroid eye disease. Its products are based on proprietary antibody technologies, namely, HexaBody, DuoBody, DuoHexaBody, and HexElect technologies. The company works in partnership with various pharmaceutical and biotechnology companies for the co-development and commercialization of antibody-based products. It operates in Denmark, the Netherlands, Japan, and the US. Genmab is headquartered in Copenhagen, Denmark.
The company reported revenues of (US Dollars) US$2,408.8 million for the fiscal year ended December 2023 (FY2023), an increase of 13.6% over FY2022. In FY2023, the company’s operating margin was 32.3%, compared to an operating margin of 43.2% in FY2022. In FY2023, the company recorded a net margin of 26.4%, compared to a net margin of 37.6% in FY2022.
The company reported revenues of US$789.9 million for the second quarter ended June 2024, an increase of 30.4% over the previous quarter.
For a complete picture of GEN-1184’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
